free web hit counter Press "Enter" to skip to content

Scalp Cooling to Avoid Loss Of Hair from Chemo Cleared in US for Solid Growth Patients

Oncology Thanks to a brand-new FDA clearance, cancer clients with strong tumors undergoing chemotherapy will now have the capability to have their scalp cooled by the DigniCap system to assist avoid loss of hair. Formerly only indicated for breast cancer clients, the DigniCap Cooling System moves cool liquid through a cap used by a client during chemo sessions.Cooling of the scalp narrows the blood vessels in the layers of tissue from which hair grows, which helps to keep the chemo agents out, and the cooler temperature level also decreases biochemical processes that participate in the chemo consumption. The result is decreased loss of hair, the amount which obviously depends on the client and drug dose delivered.The FDA keeps in mind that pediatric clients, those with specific cancers, and particular chemo routines are not encouraged to have actually the DigniCap recommended to them.Some notes from the FDA on how the broadened clearance came about: In 2015, the FDA approved marketing permission of the DigniCap for usage in clients with breast cancer. For that permission

, the efficacy of the cooling system was studied in 122 Stage I and Stage II ladies with breast cancer who were undergoing chemotherapy, utilizing recognized chemotherapy programs that have actually been associated with loss of hair. That study showed that more than 66 percent of clients treated with the DigniCap reported losing less than half their hair. In support of the expanded usage of the device, the maker also submitted proof from published, peer-reviewed posts that evaluated the application of the DigniCap to cancer clients with solid tumors in other areas of the body besides the breast. The FDA concluded that these studies provided legitimate scientific proof to support the safety and effectiveness of the expanded indicator for the DigniCap.The device is contraindicated for pediatric clients, clients with particular cancers and patient undergoing particular chemotherapy treatments. Furthermore, DigniCap may not be appropriate for clients with cold sensitivity or susceptibility to cold-related injuries.